The British drugmaker reached a $2.2 billion settlement to resolve around 80,000 lawsuits over claims its Zantac heartburn ...

KEY TAKEAWAYS GSK shares in London jumped 5% Thursday after the British pharmaceutical giant said it has resolved most of the ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of ...

GSK could still cause problems for the British firm: UBS. GlaxoSmithKline (GSK) saw its shares jump more than 6% after the ...

Shares of GSK are seen rising 5% according to pre-market indications on Thursday after the British drugmaker agreed to pay up ...

GSK's $2.2bn payment to settle 93% of outstanding Zantac lawsuits in the US was close to the "best case scenario", according ...

GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion.

GSK agreed to pay more than $2 billion to settle almost all remaining liability cases in the U.S. over allegations its ...

GSK said it expects to take a charge of £1.8 billion ($2.3 billion) in its third-quarter results in relation to the ...

SHARES of British drugmaker GSK rose as much as 6.5 per cent on Thursday (Oct 10), after it agreed to pay up to US$2.2 ...

Under the agreement, whose terms are confidential, GSK will make an "aggregate payment of up to $2.2 billion" to resolve ...

GSK has agreed to pay up to $2.2 billion to settle most pending U.S. state court lawsuits claiming that a discontinued ...